ADA Scientific Sessions 2025 Abstract

Safety and Pharmacokinetics of MBX 1416, a Glucagon-Like Peptide 1 Receptor Antagonist, in Healthy Volunteers—A Phase 1 Randomized Trial

By Elisa Fabbrini, Patricia A. Carney, Anastasiya Koshkina, Kristi L. Schneider, Salomon Azoulay

Trial in peopleInterventions

The paper

Elisa Fabbrini, Patricia A. Carney, Anastasiya Koshkina, Kristi L. Schneider, Salomon Azoulay

Carmel

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 846-P

doi.org/10.2337/db25-846-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity